<DOC>
	<DOCNO>NCT01830153</DOCNO>
	<brief_summary>This trial intend test efficacy safety RAD001 patient advance sarcoma fail conventional chemotherapy .</brief_summary>
	<brief_title>RAD001 Advanced Sarcoma</brief_title>
	<detailed_description>This multicenter , phase II trial evaluate efficacy safety everolimus patient metastatic recurrent bone soft tissue sarcoma failure anthracycline and/or ifosfamide .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histologically confirm metastatic , unresectable bone soft tissue sarcomas past treatment anthracycline and/or ifosfamide disease primarily refractory progress initial response . Any drug allow use adjuvant treatment . Unidimensionally measurable disease 3 less prior chemotherapy Age 17 year old old ECOG performance status 2 less , Life expectancy 6 month less Adequate bone marrow , liver , kidney , cardiac function Written inform consent Pregnant lactating patient Patients resectable metastasis Patients history CNS metastasis Gastrointestinal stromal tumor , chondrosarcoma , neuroblastoma Hypersensitivity active substance , rapamycin derivative , excipients . Any preexist medical condition sufficient severity prevent full compliance study</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>Bone sarcoma</keyword>
	<keyword>RAD001</keyword>
	<keyword>Refractory conventional chemotherapy</keyword>
</DOC>